Two new drug options give hope to those suffering pulmonary fibrosis

November 06, 2014

Where there was once nothing … finally, something for patients suffering with a devastating lung disease. Not one, but two new drugs give hope to those running out of breath … and time.

Arlene Brescia, pulmonary fibrosis patient: “I would be huffing and puffing, a lot of shortness of breath.”

When her doctor told her the diagnosis?

Arlene Brescia: “I was devastated. I thought, ‘Oh my life is over with.’”

Pulmonary Fibrosis Foundation November Newsletter

November 05, 2014

Check out the latest Pulmonary Fibrosis Foundation newsletter. To get the latest newsletter in your inbox, subscribe at

Bristol-Myers Squibb gains option to buy Galecto Biotech for up to $444 million

November 05, 2014
Bristol-Myers Squibb gained an option to acquire Galecto Biotech, along with its experimental drug TD139 for idiopathic pulmonary fibrosis (IPF), under a deal potentially worth up to $444 million, the companies reported Monday. The transaction includes an option fee and an option exercise fee, as well as clinical and regulatory milestone payments.

IPF Drugs Approved by US FDA

October 29, 2014
The US FDA approves Esbriet® (pirfenidone) and Ofev® (nintedanib) for the treatment of idiopathic pulmonary fibrosis. Both drugs recently received the FDA’s “breakthrough therapy” designation, which accelerated the FDA review process. Esbriet is manufactured by InterMune, Inc. and Ofev is distributed by Boehringer Ingelheim Pharmaceuticals, Inc.

Pulmonary Fibrosis Foundation Announces New Programs, Redesigned Website

May 14, 2014

Continuing its ongoing commitment to the pulmonary fibrosis community, the Pulmonary Fibrosis Foundation (PFF) announces three new initiatives this week: expansion of the PFF Care Center Network, introduction of the Disease Education Webinar Series, and the launch of its new website.